Cargando…
Advances in the management of metastatic non-seminomatous germ cell tumours during the cisplatin era: a single-institution experience.
Long-term outcome was reviewed in 266 consecutive patients with metastatic non-seminomatous germ cell tumours treated at a single institution. The overall 3 year survival was 77%, and 3 year progression-free survival was 71%. Multivariate analysis identified the following clinical features as indepe...
Autores principales: | Gerl, A., Clemm, C., Schmeller, N., Hartenstein, R., Lamerz, R., Wilmanns, W. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1996
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2075932/ https://www.ncbi.nlm.nih.gov/pubmed/8883418 |
Ejemplares similares
-
Prognosis after salvage treatment for unselected male patients with germ cell tumours.
por: Gerl, A., et al.
Publicado: (1995) -
Sequential resection of residual abdominal and thoracic masses after chemotherapy for metastatic non-seminomatous germ cell tumours.
por: Gerl, A., et al.
Publicado: (1994) -
Surgery in metastatic non-seminomatous germ cell tumours.
por: Tobias, J. S.
Publicado: (1992) -
The changing role of surgery in metastatic non-seminomatous germ cell tumour.
por: Cassidy, J., et al.
Publicado: (1992) -
Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours
por: Fosså, S D, et al.
Publicado: (1999)